Skip to Main Content

Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are sticking with the caramel cream, for no particular reason. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today. …

The National Health Service in England reached a deal with Biogen (BIIB) for the Spinraza spinal muscle atrophy treatment, Reuters writes. Under the so-called managed access agreement, Biogen will provide funding for a limited time and collect effectiveness data; however, NHS England did not disclose the price it will pay for the drug. Spinraza has a U.S. list price of $750,000 for the first year and $375,000 annually thereafter. Initially, a U.K. agency declared the drug was not cost-effective, despite a discount from Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!